Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 29, 2024


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-25121

_______________________________________________________________________

SLEEP NUMBER CORPORATION

(Exact name of registrant as specified in its charter)


Minnesota		41-1597886
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)


1001 Third Avenue South
Minneapolis,	Minnesota	55404
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (763) 551-7000

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	SNBR	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted

pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the

registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller

reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller

reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 29, 2024, 22,355,000 shares of the registrant’s Common Stock were outstanding.

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

INDEX


		Page
PART I: FINANCIAL INFORMATION		1

Item 1.	Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Shareholders' Deficit	3
	Condensed Consolidated Statements of Cash Flows	4
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	26

PART II: OTHER INFORMATION		27

Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	29
SIGNATURES		30

Table of contents


i \| 3Q 2023 FORM 10-Q		SLEEP NUMBER CORPORATION

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited - in thousands, except per share amounts)


	June 29, 2024	December 30, 2023
Assets
Current assets:
Cash and cash equivalents	$2,020	$2,539
Accounts receivable, net of allowances of $1,098 and $1,437, respectively	20,272	26,859
Inventories	95,845	115,433
Prepaid expenses	21,322	16,660
Other current assets	37,925	44,637
Total current assets	177,384	206,128

Non-current assets:
Property and equipment, net	153,676	179,503
Operating lease right-of-use assets	373,518	395,411
Goodwill and intangible assets, net	66,523	66,634
Deferred income taxes	25,397	20,253
Other non-current assets	87,147	82,951
Total assets	$883,645	$950,880

Liabilities and Shareholders’ Deficit
Current liabilities:
Borrowings under revolving credit facility	$540,200	$539,500
Accounts payable	106,039	135,901
Customer prepayments	44,518	49,143
Accrued sales returns	20,531	22,402
Compensation and benefits	35,305	28,273
Taxes and withholding	16,563	17,134
Operating lease liabilities	80,914	81,760
Other current liabilities	56,500	61,958
Total current liabilities	900,570	936,071

Non-current liabilities:
Operating lease liabilities	327,810	351,394
Other non-current liabilities	102,229	105,343
Total liabilities	1,330,609	1,392,808

Shareholders’ deficit:
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding	—	—
Common stock, $0.01 par value; 142,500 shares authorized, 22,355 and 22,235 shares issued and outstanding, respectively	224	222
Additional paid-in capital	24,211	16,716
Accumulated deficit	(471,399)	(458,866)
Total shareholders’ deficit	(446,964)	(441,928)
Total liabilities and shareholders’ deficit	$883,645	$950,880

See accompanying notes to condensed consolidated financial statements.

Table of contents


1 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(unaudited - in thousands, except per share amounts)


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Net sales	$408,413	$458,789	$878,862	$985,316
Cost of sales	166,923	194,544	361,198	410,806
Gross profit	241,490	264,245	517,664	574,510

Operating expenses:
Sales and marketing	182,400	197,779	390,912	428,267
General and administrative	39,573	39,795	78,652	79,196
Research and development	11,578	15,445	24,019	29,888
Restructuring costs	1,819	—	12,419	—
Total operating expenses	235,370	253,019	506,002	537,351
Operating income	6,120	11,226	11,662	37,159
Interest expense, net	12,270	9,948	24,569	19,050
(Loss) income before income taxes	(6,150)	1,278	(12,907)	18,109
Income tax (benefit) expense	(1,099)	524	(374)	5,890
Net (loss) income	$(5,051)	$754	$(12,533)	$12,219

Basic net (loss) income per share:
Net (loss) income per share – basic	$(0.22)	$0.03	$(0.56)	$0.55
Weighted-average shares – basic	22,614	22,460	22,560	22,378

Diluted net (loss) income per share:
Net (loss) income per share – diluted	$(0.22)	$0.03	$(0.56)	$0.54
Weighted-average shares – diluted	22,614	22,502	22,560	22,543

See accompanying notes to condensed consolidated financial statements.

Table of contents


2 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Shareholders’ Deficit

(unaudited - in thousands)


	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at December 30, 2023	22,235	$222	$16,716	$(458,866)	$(441,928)
Net loss	—	—	—	(7,482)	(7,482)
Stock-based compensation	134	1	4,116	—	4,117
Repurchases of common stock	(43)	—	(570)	—	(570)
Balance at March 30, 2024	22,326	$223	$20,262	$(466,348)	$(445,863)
Net loss	—	—	—	(5,051)	(5,051)
Stock-based compensation	32	1	3,991	—	3,992
Repurchases of common stock	(3)	—	(42)	—	(42)
Balance at June 29, 2024	22,355	$224	$24,211	$(471,399)	$(446,964)


	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at December 31, 2022	22,014	$220	$5,182	$(443,579)	$(438,177)
Net income	—	—	—	11,465	11,465
Exercise of common stock options	17	—	389	—	389
Stock-based compensation	271	3	4,636	—	4,639
Repurchases of common stock	(118)	(1)	(3,362)	—	(3,363)
Balance at April 1, 2023	22,184	$222	$6,845	$(432,114)	$(425,047)
Net income	—	—	—	754	754
Exercise of common stock options	3	—	39	—	39
Stock-based compensation	33	—	5,251	—	5,251
Repurchases of common stock	(6)	—	(138)	—	(138)
Balance at July 1, 2023	22,214	$222	$11,997	$(431,360)	$(419,141)

See accompanying notes to condensed consolidated financial statements.

Table of contents


3 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited - in thousands)


	Six Months Ended
	June 29, 2024	July 1, 2023
Cash flows from operating activities:
Net (loss) income	$(12,533)	$12,219
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	34,177	36,749
Stock-based compensation	8,109	9,890
Net loss on disposals and impairments of assets	2,500	181
Deferred income taxes	(5,144)	(8,272)
Changes in operating assets and liabilities:
Accounts receivable	6,587	1,903
Inventories	19,588	(7,412)
Income taxes	774	1,808
Prepaid expenses and other assets	(1,483)	(5,824)
Accounts payable	(18,464)	(10,244)
Customer prepayments	(4,625)	(14,683)
Accrued compensation and benefits	7,153	7,594
Other taxes and withholding	(1,345)	(2,074)
Other accruals and liabilities	(11,776)	(3,115)
Net cash provided by operating activities	23,518	18,720

Cash flows from investing activities:
Purchases of property and equipment	(14,075)	(29,899)
Issuance of note receivable	(2,942)	(435)
Net cash used in investing activities	(17,017)	(30,334)

Cash flows from financing activities:
Net (decrease) increase in short-term borrowings	(6,408)	14,693
Repurchases of common stock	(612)	(3,501)
Proceeds from issuance of common stock	—	428
Net cash (used in) provided by financing activities	(7,020)	11,620

Net (decrease) increase in cash and cash equivalents	(519)	6
Cash and cash equivalents, at beginning of period	2,539	1,792
Cash and cash equivalents, at end of period	$2,020	$1,798

See accompanying notes to condensed consolidated financial statements.

Table of contents


4 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

1. Business and Summary of Significant Accounting Policies

Business & Basis of Presentation

The Company prepared the condensed consolidated financial statements as of and for the three and six months ended

June 29, 2024 of Sleep Number Corporation and its 100%-owned subsidiaries (Sleep Number or the Company), without

audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) and they reflect, in the

opinion of management, all normal recurring adjustments, including the elimination of all significant intra-entity balances

and transactions, necessary to present fairly its financial position as of June 29, 2024 and December 30, 2023, and the

consolidated results of operations and cash flows for the periods presented. The historical and quarterly consolidated

results of operations may not be indicative of the results that may be achieved for the full year or any future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.

generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and

regulations. These condensed consolidated financial statements should be read in conjunction with the most recent

audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for

the fiscal year ended December 30, 2023 and other recent filings with the SEC.

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to

make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities,

disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the

reported amounts of sales, expenses and income taxes during the reporting period. Predicting future events is inherently

an imprecise activity and, as such, requires the use of judgment. As future events and their effects cannot be determined

with precision, actual results could differ significantly from these estimates. Changes in these estimates will be reflected

in the consolidated financial statements in future periods and could be material. The Company’s critical accounting

policies consist of stock-based compensation, warranty liabilities and revenue recognition.

2. Fair Value Measurements

At both June 29, 2024 and December 30, 2023, the Company had $19 million of debt and equity securities that fund the

deferred compensation plan and are classified in other non-current assets. The Company also had corresponding

deferred compensation plan liabilities of $19 million at both June 29, 2024 and December 30, 2023, which are included

in other non-current liabilities. The majority of the debt and equity securities are Level 1 as they trade with sufficient

frequency and volume to enable the Company to obtain pricing information on an ongoing basis. Unrealized gains/

(losses) on the debt and equity securities offset those associated with the corresponding deferred compensation plan

liabilities.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


5 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

3. Inventories

Inventories consisted of the following (in thousands):


	June 29, 2024	December 30, 2023
Raw materials	$7,899	$9,092
Work in progress	94	92
Finished goods	87,852	106,249
	$95,845	$115,433

4. Goodwill and Intangible Assets, Net

Goodwill and Indefinite-lived Intangible Assets

Goodwill was $64 million at June 29, 2024 and December 30, 2023. Indefinite-lived trade name/trademarks totaled $1.4

million at both June 29, 2024 and December 30, 2023.

Definite-lived Intangible Assets

Patents were $2.0 million at both June 29, 2024 and December 30, 2023. Accumulated amortization was $0.9 million at

June 29, 2024 and $0.8 million at December 30, 2023. Amortization expense for both the three months ended June 29,

2024 and July 1, 2023, was $55 thousand, and for both the six months ended June 29, 2024 and July 1, 2023 was

$0.1 million.

Annual amortization for Patents for subsequent years are as follows (in thousands):


2024 (excluding the six months ended June 29, 2024)		$111
2025		226
2026		222
2027		222
2028		155
2029		99
Thereafter		46
Total future amortization for definite-lived intangible assets		$1,081

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


6 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

5. Credit Agreement

As of June 29, 2024, the Company’s credit facility had a total commitment amount of $680 million. The credit facility is

for general corporate purposes, to meet seasonal working capital requirements and to repurchase its stock. The Credit

Agreement includes an accordion feature which allows the Company to increase the amount of the credit facility from

$680 million to $1.0 billion, subject to lenders’ approval. The Credit Agreement provides the lenders with a collateral

security interest in substantially all of the Company’s assets and those of its subsidiaries and requires the Company to

comply with, among other things, a maximum net leverage ratio and a minimum interest coverage ratio.

The maximum net leverage ratio permitted by the Credit Agreement is 5.50 to 1.00 for the quarterly period ended

June 29, 2024; 5.00 to 1.00 for the quarterly reporting period ending September 28, 2024; 4.80 to 1.00 for the quarterly

reporting period ending December 28, 2024; and 4.00 to 1.00 for each quarterly reporting period occurring thereafter.

The minimum interest coverage ratio permitted by the Credit Agreement is 1.25 to 1.00 for the quarterly period ended

June 29, 2024; 1.50 to 1.00 for the quarterly reporting periods ending September 28, 2024 and December 28, 2024; and

3.00 to 1.00 for each quarterly reporting period occurring thereafter.

The carrying amount of the outstanding borrowings under the Credit Agreement approximates fair value because

interest rates approximate the current rates available to the Company. Under the terms of the Credit Agreement, the

Company pays a variable rate of interest and a commitment fee based on its leverage ratio. The Credit Agreement

matures in December 2026. The Company was in compliance with all financial covenants as of June 29, 2024.

The following table summarizes the Company’s borrowings under the credit facility ($ in thousands):


	June 29, 2024	December 30, 2023
Outstanding borrowings	$540,200	$539,500
Outstanding letters of credit	$7,147	$7,147
Additional borrowing capacity	$132,653	$138,353
Weighted-average interest rate	8.4%	8.5%

6. Leases

The Company leases its retail, office and manufacturing space under operating leases which, in addition to the minimum

lease payments, may require payment of a proportionate share of the real estate taxes and certain building operating

expenses. While the Company’s local market development approach generally results in long-term participation in given

markets, the retail store leases generally provide for an initial lease term of five to 10 years. The Company’s office and

manufacturing leases provide for an initial lease term of up to 15 years. In addition, the Company’s mall-based retail

store leases may require payment of variable rent based on net sales in excess of certain thresholds. Certain leases may

contain options to extend the term of the original lease. The exercise of lease renewal options is at the Company’s sole

discretion. Lease options are included in the lease term only if exercise is reasonably certain at lease commencement.

The Company’s lease agreements do not contain any material residual value guarantees. The Company also leases

vehicles and certain equipment under operating leases with an initial lease term of three to six years.

The Company’s operating lease costs include facility, vehicle and equipment lease costs, but exclude variable lease

costs. Operating lease costs are recognized on a straight-line basis over the lease term, after consideration of rent

escalations and rent holidays. The lease term for purposes of the calculation begins on the earlier of the lease

commencement date or the date the Company takes possession of the property. During lease renewal negotiations that

extend beyond the original lease term, the Company estimates straight-line rent expense based on current market

conditions. Variable lease costs are recorded when it is probable the cost has been incurred and the amount can be

reasonably estimated.

At June 29, 2024, the Company’s finance right-of-use assets and lease liabilities were not significant.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


7 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Lease costs were as follows (in thousands):


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Operating lease costs(1)	$26,909	$28,083	$53,735	$56,372
Variable lease costs(2)	$8	$129	$(41)	$182

___________________________

(1)Includes short-term lease costs which are not significant.

(2)Variable lease costs include adjustments to percentage rent.

The maturities of operating lease liabilities as of June 29, 2024, were as follows(1) (in thousands):


2024 (excluding the six months ended June 29, 2024)	$53,107
2025	100,672
2026	88,780
2027	72,728
2028	60,841
2029	41,075
Thereafter	71,244
Total operating lease payments(2)	488,447
Less: Interest	79,723
Present value of operating lease liabilities	$408,724

___________________________

(1)Future payments for real estate taxes and certain building operating expenses for which the Company is obligated are not included in the operating

lease liabilities. Total operating lease payments exclude $19 million of legally binding minimum lease payments for leases signed but not yet

commenced.

(2)Includes the current portion of $81 million for operating lease liabilities.

Other information related to operating leases was as follows:


	June 29, 2024	December 30, 2023
Weighted-average remaining lease term (in years)	5.7	5.9
Weighted-average discount rate	6.6%	6.5%


	Six Months Ended
(in thousands)	June 29, 2024	July 1, 2023
Cash paid for amounts included in present value of operating lease liabilities	$54,300	$53,476
Right-of-use assets obtained in exchange for operating lease liabilities	$16,313	$32,831

7. Repurchases of Common Stock

For the three months ended June 29, 2024 and July 1, 2023, we repurchased $42 thousand and $138 thousand,

respectively, of common stock in connection with the vesting of restricted stock grants. For the six months ended

June 29, 2024 and July 1, 2023, we repurchased $0.6 million and $3.5 million, respectively, of common stock in

connection with the vesting of restricted stock grants. We made no purchases under the Board-approved stock purchase

plan in either period. As of June 29, 2024, the remaining authorization under the Board-approved $600 million share

repurchase program was $348 million.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


8 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

8. Revenue Recognition

Deferred contract assets and deferred contract liabilities are included in the condensed consolidated balance sheets as

follows (in thousands):


	June 29, 2024	December 30, 2023
Deferred contract assets included in:
Other current assets	$29,771	$28,567
Other non-current assets	52,312	54,795
	$82,083	$83,362


	June 29, 2024	December 30, 2023
Deferred contract liabilities included in:
Other current liabilities	$37,720	$36,421
Other non-current liabilities	65,362	69,098
	$103,082	$105,519

Deferred revenue and costs related to SleepIQ® technology are currently recognized on a straight-line basis over the

product's estimated life of 4.5 to 5.0 years because the Company’s inputs are generally expended evenly throughout the

performance period. During both the three months ended June 29, 2024 and July 1, 2023, the Company recognized

revenue of $10 million, that was included in the deferred contract liability balances at the beginning of the respective

periods. During both the six months ended June 29, 2024 and July 1, 2023, the Company recognized revenue of $19

million, that was included in the deferred contract liability balances at the beginning of the respective periods.

Revenue from goods and services transferred to customers at a point in time accounted for approximately 98% of

revenues for both the three and six months ended June 29, 2024 and July 1, 2023.

Net sales were as follows (in thousands):


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Retail stores	$358,584	$402,145	$773,339	$860,808
Online, phone, chat and other	49,829	56,644	105,523	124,508
Total Company	$408,413	$458,789	$878,862	$985,316

Obligation for Sales Returns

The activity in the sales returns liability account was as follows (in thousands):


	Six Months Ended
	June 29, 2024	July 1, 2023
Balance at beginning of year	$22,402	$25,594
Additions that reduce net sales	46,664	57,849
Deductions from reserves	(48,535)	(57,967)
Balance at end of period	$20,531	$25,476

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


9 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

9. Stock-based Compensation Expense

Total stock-based compensation expense was as follows (in thousands):


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Stock awards (1)	$3,294	$4,258	6,438	$8,113
Stock options	698	994	1,671	1,777
Total stock-based compensation expense (1)	3,992	5,252	8,109	9,890
Income tax benefit	809	1,417	1,719	2,670
Total stock-based compensation expense, net of tax	$3,183	$3,835	$6,390	$7,220

___________________________

(1) Changes in stock-based compensation expense include the cumulative impact of the change in the expected achievements of certain performance

targets.

10. Profit Sharing and 401(k) Plan

Under the Company’s profit sharing and 401(k) plan, eligible employees may defer up to 50% of their compensation on a

pre-tax basis, subject to Internal Revenue Service limitations. Each pay period, the Company makes a contribution equal

to a percentage of the employee’s contribution. During the three months ended June 29, 2024 and July 1, 2023, the

Company’s contributions, net of forfeitures, were $1.2 million and $2.8 million, respectively and during the six months

ended June 29, 2024 and July 1, 2023, were $3.2 million and $5.2 million, respectively.

11. Net Income per Common Share

The components of basic and diluted net (loss) income per share were as follows (in thousands, except per share

amounts):


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Net (loss) income	$(5,051)	$754	$(12,533)	$12,219
Reconciliation of weighted-average shares outstanding:
Basic weighted-average shares outstanding	22,614	22,460	22,560	22,378
Dilutive effect of stock-based awards	—	42	—	165
Diluted weighted-average shares outstanding	22,614	22,502	22,560	22,543
Net (loss) income per share – basic	$(0.22)	$0.03	$(0.56)	$0.55
Net (loss) income per share – diluted	$(0.22)	$0.03	$(0.56)	$0.54

For the three and six months ended June 29, 2024, otherwise dilutive stock-based awards have been excluded from the

calculation of diluted weighted-average shares outstanding, as their inclusion would have had an anti-dilutive effect on

our net loss per diluted share. Additional potential dilutive stock-based awards totaling 1.3 million for both the three

months ended June 29, 2024 and July 1, 2023, and 1.3 million and 1.2 million for the six months ended June 29, 2024

and July 1, 2023, respectively, have been excluded from the diluted net (loss)/income per share calculations because

these stock-based awards were anti-dilutive.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


10 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

12. Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs

incurred in 2023, the Company incurred an additional $1.8 million and $12.4 million of restructuring costs during the

three and six months ended June 29, 2024, respectively. Charges incurred related to this initiative were comprised of

contract termination costs, severance and employee-related benefits, professional fees and other, and asset impairment

charges and are included in the restructuring costs line in the Company’s consolidated statement of operations. The

Company expects an additional $1 million to $2 million of restructuring costs to be incurred through the remainder of

2024.

During the three and six months ended June 29, 2024, the Company recognized $1.8 million and $12.4 million of

restructuring costs, respectively, as follows (in thousands):


	Three Months Ended	Six Months Ended
	June 29, 2024	June 29, 2024
Cash restructuring costs:
Contract termination costs (1)	$(230)	$4,183
Severance and employee-related benefits	401	1,242
Professional fees and other	1,648	4,494
Total cash restructuring costs	1,819	9,919
Non-cash restructuring costs:
Asset impairments (2)	—	2,500
Total restructuring costs	$1,819	$12,419

____________________

(1) Primarily comprised of lease termination costs. The three months ended June 29, 2024 include a change in estimate.

(2) Primarily comprised of impairments of property and equipment.

The following table provides the activity in the Company’s restructuring related liabilities, which are included within

accounts payable, compensation and benefits and other current liabilities on the consolidated balance sheet (in

thousands):


			Six Months Ended
			June 29, 2024
Balance at the beginning of year			$8,720
Expenses			9,919
Cash payments			(16,916)
Balance at the end of the period			$1,723

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


11 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Since the initiation of cost reduction actions in the fourth quarter of 2023, the Company has recognized a cumulative

$28.1 million of restructuring costs, as follows (in thousands):


		Cumulative
		June 29, 2024
Cash restructuring costs:
Contract termination costs (1)		$11,593
Severance and employee-related benefits		6,208
Professional fees and other		5,604
Total cash restructuring costs		23,405
Non-cash restructuring costs:
Asset impairments (2)		4,742
Total restructuring costs		$28,147

____________________

(1)Primarily comprised of lease termination costs.

(2) Includes impairments of both lease right-of-use assets and property and equipment.

13. Commitments and Contingencies

Warranty Liabilities

The activity in the accrued warranty liabilities account was as follows (in thousands):


	Six Months Ended
	June 29, 2024	July 1, 2023
Balance at beginning of period	$8,503	$8,997
Additions charged to costs and expenses for current-year sales	7,675	8,194
Deductions from reserves	(8,048)	(8,315)
Changes in liability for pre-existing warranties during the current year, including expirations	(171)	111
Balance at end of period	$7,959	$8,987

Legal Proceedings

The Company is involved from time to time in various legal proceedings arising in the ordinary course of its business,

including primarily commercial, product liability, employment and intellectual property claims. In accordance with U.S.

generally accepted accounting principles, the Company records a liability in its consolidated financial statements with

respect to any of these matters when it is both probable that a liability has been incurred and the amount of the liability

can be reasonably estimated. If a material loss is reasonably possible but not known or probable, and may be reasonably

estimated, the estimated loss or range of loss is disclosed. With respect to currently pending legal proceedings, the

Company has not established an estimated range of reasonably possible material losses either because it believes that is

has valid defenses to claims asserted against it, the proceeding has not advanced to a stage of discovery that would

enable it to establish an estimate, or the potential loss is not material. The Company currently does not expect the

outcome of pending legal proceedings to have a material effect on its consolidated results of operations, financial

position or cash flows. Litigation, however, is inherently unpredictable, and it is possible that the ultimate outcome of

one or more claims asserted against the Company could adversely impact its consolidated results of operations, financial

position or cash flows. The Company expenses legal costs as incurred.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


12 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Purported Class Action Complaint

On December 15, 2023, a former Field Services team member filed a purported class action Complaint in the Superior

Court of California, County of Santa Clara, alleging violations of California’s meal and rest break law and additional wage

and hour derivative claims under the California Labor Code. While the representative plaintiff was in the Field Services

workforce, the Complaint does not limit the purported plaintiff class to that group, but rather extends to all non-exempt

Sleep Number employees in the state. The plaintiff alleges that Sleep Number failed to provide compliant meal or rest

breaks, failed to pay wages owed due to alleged off the clock work, failed to pay overtime, minimum wage and wages

due at termination, thus resulting in inaccurate wage statements, all in violation of California law. The Complaint seeks

damages in the form of unpaid regular and premium wages, statutory penalties, pre-judgment and post-judgment

interest, plaintiffs’ attorneys’ fees and costs. On February 22, 2024, the plaintiff filed a related lawsuit in the same county

alleging violations of a broad range of California Labor Code wage and hour violations under the state’s Private Attorney

General Act (PAGA), including the same meal and rest break, and wage and hour, violations as appear in the purported

class action. Sleep Number has a pending motion to compel arbitration which includes a request to enforce the class

action waiver that the former Field Services team member signed when they agreed to arbitrate any employment

disputes. The Court stayed the PAGA case pending resolution of the motion to compel arbitration in the purported class

action case.

Shareholder Class Action Complaints

On December 14, 2021, purported Sleep Number shareholder, Steamfitters Local 449 Pension & Retirement Security

Funds (Steamfitters), filed a putative class action complaint in the United States District Court for the District of

Minnesota (the District of Minnesota) on behalf of all purchasers of Sleep Number common stock between February 18,

2021 and July 20, 2021, inclusive, against Sleep Number, Shelly Ibach and David Callen, the Company’s former

Executive Vice President and Chief Financial Officer. Steamfitters alleges material misstatements and omissions in certain

of Sleep Number’s public disclosures during the purported class period, in violation of Sections 10(b) and 20(a) of the

Securities Exchange Act of 1934, as amended (the Exchange Act). The complaint seeks, among other things, unspecified

monetary damages, reasonable costs and expenses and equitable/injunctive or other relief as deemed appropriate by

the District of Minnesota.

On February 14, 2022, a second purported Sleep Number shareholder, Ricardo Dario Schammas, moved for

appointment as lead plaintiff in the action. On March 24, 2022, the District of Minnesota heard argument on Schammas’s

motion, and subsequently appointed Steamfitters and Schammas as Co-Lead Plaintiffs (together, Co-Lead Plaintiffs). On

July 19, 2022, Co-Lead Plaintiffs filed a consolidated amended complaint, which, like the predecessor complaint, asserts

claims against Sleep Number, Shelly Ibach, and David Callen under Sections 10(b) and 20(a) of the Exchange Act. Co-

Lead Plaintiffs purport to assert these claims on behalf of all purchasers of Sleep Number common stock between

February 18, 2021 and July 20, 2021. On September 19, 2022, Defendants moved to dismiss the consolidated amended

complaint, which motion was heard by the Court on January 17, 2023. On July 10, 2023, the Court issued an order

dismissing the Plaintiffs’ consolidated amended complaint with prejudice.

Shareholder Derivative Complaint

On May 12, 2022, Gwendolyn Calla Moore, as the appointed representative of purported Sleep Number shareholder

Matthew Gelb, filed a derivative action (the Derivative Action) in the District of Minnesota against Jean-Michel Valette,

Shelly Ibach, Barbara Matas, Brenda Lauderback, Daniel Alegre, Deborah Kilpatrick, Julie Howard, Kathleen Nedorostek,

Michael Harrison, Stephen Gulis, Jr., David Callen, and Kevin Brown. Moore purports to assert claims on behalf of Sleep

Number for breaches of fiduciary duty, waste, and contribution under Sections 10(b) and 21(d) of the Exchange Act.

Moore’s allegations generally mirror those asserted in the securities complaint described above. The Moore complaint

seeks damages in an unspecified amount, disgorgement, interest, and costs and expenses, including attorneys’ and

experts’ fees.

On September 13, 2022, the District of Minnesota entered a joint stipulation staying all proceedings in the Derivative

Action pending the outcome of any motion to dismiss the Steamfitters consolidated amended complaint. On July 10,

2023, the District of Minnesota in the Steamfitters case dismissed the consolidated amended complaint with prejudice,

as noted above. The Plaintiff in the Derivative Action subsequently moved the Court to voluntarily dismiss its the

Complaint and on January 22, 2024, the District of Minnesota dismissed the Derivative Action without prejudice.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


13 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Stockholder Demand

On March 25, 2022, Sleep Number received a shareholder litigation demand (the “Demand”), requesting that the Board

investigate the allegations in the Steamfitters complaint and pursue claims on Sleep Number’s behalf based on those

allegations. On May 12, 2022, the Board established a special litigation committee to investigate the demand.

On October 5 and October 12, 2022, Sleep Number received two additional shareholder litigation demands, which

adopted and incorporated the allegations and requests in the Demand. Both of these additional litigation demands were

referred to the special litigation committee.

Subsequently, the special litigation committee determined that it would not be in the best interests of the Company and

its shareholders to take the actions requested in the demands and, thus, rejected the demands in their entirety.

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)


14 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide

a reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of

management on its financial condition, results of operations, liquidity and certain other factors that may affect the

Company’s future results. MD&A is presented in seven sections:

•Forward-Looking Statements and Risk Factors

•Business Overview

•Results of Operations

•Liquidity and Capital Resources

•Non-GAAP Data Reconciliations

•Off-Balance-Sheet Arrangements and Contractual Obligations

•Critical Accounting Policies

Forward-looking Statements and Risk Factors

The discussion in this Quarterly Report contains certain forward-looking statements that relate to future plans,

events, financial results or performance. You can identify forward-looking statements by those that are not

historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,” “expect,”

“anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or the negative

of these or similar terms. These statements are subject to certain risks and uncertainties that could cause actual

results to differ materially from the Company’s historical experience and its present expectations or projections.

These risks and uncertainties include, among others:

•Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;

•Increases in interest rates, which have increased the cost of servicing the Company’s indebtedness;

•Availability of attractive and cost-effective consumer credit options;

•Ability to achieve savings and efficiencies from cost savings plans related to business restructuring actions and to

avoid unexpected adverse effects;

•Dependence on, and ability to maintain working relationships and favorable contractual terms with key suppliers and

third parties;

•Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;

•Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,

labor challenges, foreign currency fluctuations, inflation, and climate or other disasters, and resulting supply

shortages and production and delivery delays and disruptions;

•Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages, as well as

carrying excess levels of inventory for various products from time to time, which may leave the Company vulnerable

to inventory obsolescence and write-downs;

•The effectiveness of the Company’s marketing strategy and promotional efforts;

•The execution of Sleep Number’s Total Retail distribution strategy;

•Ability to achieve and maintain high levels of product quality and to improve and expand the product line;

•Ability to protect the Company’s technology, trademarks, and brand and the adequacy of its intellectual property

rights;

•Ability to effectively compete;

•Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,

assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer

service operations;

•Ability to comply with existing and changing government regulations and laws;

•Pending or unforeseen litigation and the potential for associated adverse publicity;

•The adequacy of the Company’s and third-party information systems and costs and disruptions related to upgrading

or maintaining these systems;

Index


15 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

•The Company’s ability to identify and withstand cyber threats that could compromise the security of its systems,

result in a data breach or business disruption;

•Risks associated with advancements in or adoption of artificial intelligence technologies;

•Sleep Number’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and

effective personnel;

•The volatility of Sleep Number stock, its removal from various stock indices, and the potential negative effects of

shareholder activism or of changes in coverage by securities analysts;

•Environmental, social and governance risks, including increasing regulation and stakeholder expectations; and

•The Company’s ability to adapt to climate change and readiness for legal or regulatory responses thereto.

Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk

Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent

Quarterly Reports on Form 10-Q.

The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this

Quarterly Report on Form 10-Q.

Business Overview

Sleep Number is a wellness technology company and market leader in the design, manufacturing, marketing and

distribution of highly innovative sleep solutions. The Company’s purpose is to improve the health and wellbeing of

society through higher quality sleep; to date, it has improved the lives of over 15 million people. Sleep Number’s Smart

Sleepers benefit from individualized sleep experiences, night after night, and are experiencing the physical, mental and

emotional benefits of life-changing sleep.

Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating

unparalleled physical comfort with a highly advanced technology platform. The smart beds offer the Company’s

signature firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep

needs of each individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep

the sleeper comfortable throughout the night. Active temperature balancing technology supports the ideal climate for

both sleepers and solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with

personalized sleep insights delivered daily, new features regularly added to all smart beds through over-the-air updates,

and prices to meet most budgets. Sleep Number® smart beds provide unmatched features, benefits and comfort that

can lead to improved sleep health and wellness for both sleepers.

The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized sleep

wellness platform, a network of highly engaged Smart Sleepers, a vertically integrated operating model, and a culture of

individuality, with an ambitious vision to become one of the world’s most beloved brands. Sleep Number’s exclusive

distribution meets its customers whenever and wherever they choose – through digital and in-store touchpoints – to

provide an exceptional experience and a lifelong relationship. The Company partners with world-leading institutions to

bring the power of nearly 28 billion hours of longitudinal sleep data to sleep science and research. And Sleep Number’s

3,800 purpose-driven team members are dedicated to the Company’s mission of improving lives by individualizing sleep

experiences.

Sleep Number is focused on cost improvement through broad-based restructuring actions to become a stronger, more

durable company, poised for accelerating growth and superior shareholder returns as the bedding industry demand

environment improves. The Company generates revenue by marketing and selling its innovative smart beds directly to

new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including

Stores, Online, Phone, and Chat (Total Retail).

Index


16 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Results of Operations

Quarterly and Year-to-Date Results

Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including

increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return

rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/

closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new

product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity

costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,

consumer sentiment and general economic conditions. The extent to which these external factors will impact the

Company’s business and its consolidated financial results will depend on future developments, which are highly

uncertain and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that

may be achieved for any future period.

Highlights

Financial highlights for the three months ended June 29, 2024 were as follows:

•Net sales for the three months ended June 29, 2024 of $408 million decreased 11% from $459 million for the same

period one year ago. The mattress industry is in a historic recession, consumer purchasing power remains limited,

and consumers are scrutinizing their spending.

•The net sales change resulted from an 11% comparable sales decrease in Total Retail. For additional details, see the

components of total net sales change on page 19.

•Sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a trailing

twelve-month basis for the period ended June 29, 2024 totaled $2.7 million, compared with $3.1 million for the

same period last year.

•Operating income for the three months ended June 29, 2024 was $6 million, compared with $11 million in the prior-

year period. The $5 million decrease in operating income was driven by the lower net sales offset by a 1.5 ppt.

increase in the gross profit rate, and an $18 million reduction in operating expenses. Operating expenses for the

three months ended June 29, 2024 included $2 million of restructuring costs.

•Adjusted EBITDA for the three months ended June 29, 2024 was $28 million, compared to $35 million in the prior-

year period as ongoing cost reduction actions partially offset the year-over-year net sales decline.

•The 1.5 ppt. gross profit rate increase was primarily due to improvement in commodity prices and operating

efficiencies. See the Gross profit discussion on page 20 for additional details.

•The $18 million reduction in the Company’s operating expenses was due to lower sales and marketing and research

and development expenses, partly offset by $2 million of restructuring costs.

•Net loss for the three months ended June 29, 2024 was $5 million, compared with net income of $1 million for the

same period one year ago. Net loss per diluted share was $0.22, compared with net income per diluted share of

$0.03 for the comparable period one year ago.

•The Company’s adjusted return on invested capital (Adjusted ROIC) was 3.7% on a trailing twelve-month basis for

the period ended June 29, 2024, compared with 12.3% for the comparable period one year ago.

•The Company generated $24 million in cash from operating activities for the six months ended June 29, 2024,

compared with $19 million for the same period one year ago.

•Free cash flow provided $9 million for the six months ended June 29, 2024, compared with using $11 million for the

same period one year ago.

•As of June 29, 2024, the Company had $540 million of borrowings under its revolving credit facility.


17 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.

Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.


	Three Months Ended				Six Months Ended
	June 29, 2024		July 1, 2023		June 29, 2024		July 1, 2023
Net sales	$408.4	100.0%	$458.8	100.0%	$878.9	100.0%	$985.3	100.0%
Cost of sales	166.9	40.9%	194.5	42.4%	361.2	41.1%	410.8	41.7%
Gross profit	241.5	59.1%	264.3	57.6%	517.7	58.9%	574.5	58.3%
Operating expenses:
Sales and marketing	182.4	44.7%	197.8	43.1%	390.9	44.5%	428.3	43.5%
General and administrative	39.6	9.7%	39.8	8.7%	78.7	8.9%	79.2	8.0%
Research and development	11.6	2.8%	15.4	3.4%	24.0	2.7%	29.9	3.0%
Restructuring costs	1.8	0.4%	—	0.0%	12.4	1.4%	—	0.0%
Total operating expenses	235.4	57.6%	253.0	55.1%	506.0	57.6%	537.4	54.5%
Operating income	6.1	1.5%	11.2	2.4%	11.7	1.3%	37.2	3.8%
Interest expense, net	12.3	3.0%	9.9	2.2%	24.6	2.8%	19.1	1.9%
(Loss) income before income taxes	(6.2)	(1.5%)	1.3	0.3%	(12.9)	(1.5%)	18.1	1.8%
Income tax (benefit) expense	(1.1)	(0.3%)	0.5	0.1%	(0.4)	0.0%	5.9	0.6%
Net (loss) income	$(5.1)	(1.2%)	$0.8	0.2%	$(12.5)	(1.4%)	$12.2	1.2%

Net (loss) income per share:
Basic	$(0.22)		$0.03		$(0.56)		$0.55
Diluted	$(0.22)		$0.03		$(0.56)		$0.54

Weighted-average number of common shares:
Basic	22.6		22.5		22.6		22.4
Diluted	22.6		22.5		22.6		22.5

The percentage of total net sales, by dollar volume, was as follows:


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Retail stores	87.8%	87.7%	88.0%	87.4%
Online, phone, chat and other	12.2%	12.3%	12.0%	12.6%
Total Company	100.0%	100.0%	100.0%	100.0%


18 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

The components of total net sales change, including comparable net sales changes, were as follows:


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Sales change rates:
Retail comparable-store sales (1)	(11%)	(20%)	(10%)	(10%)
Online, phone and chat	(13%)	(3%)	(16%)	(12%)
Total Retail comparable sales change (1)	(11%)	(18%)	(11%)	(10%)
Net opened/closed stores and other	0%	2%	0%	2%
Total Company	(11%)	(16%)	(11%)	(8%)

___________________________

(1)Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned

within the same shopping center remain in the comparable-store base.

Other sales metrics were as follows:


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Average sales per store (1) (in thousands)	$2,732	$3,089
Average sales per square foot (1)	$883	$1,007
Stores > $2 million in net sales (2)	62%	71%
Stores > $3 million in net sales (2)	21%	31%
Average revenue per smart bed unit (3)	$5,802	$5,990	$5,782	$5,913

___________________________

(1)Trailing-twelve months Total Retail comparable sales per store open at least one year.

(2)Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).

(3)Represents Total Retail net sales divided by Total Retail smart bed units.

The number of retail stores operating was as follows:


	Three Months Ended		Six Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Beginning of period	661	671	672	670
Opened	4	7	10	19
Closed	(19)	(6)	(36)	(17)
End of period	646	672	646	672


19 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Comparison of Three Months Ended June 29, 2024 with Three Months Ended July 1, 2023

Net sales

Net sales for the three months ended June 29, 2024 of $408 million decreased 11% from $459 million for the same

period one year ago. The mattress industry is in a historic recession, consumer purchasing power remains limited, and

consumers are scrutinizing their spending.

The net sales change consisted primarily of an 11% comparable sales decrease in Total Retail.

The $50.4 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a

$40.2 million decrease in Retail comparable net sales; (ii) a $7.0 million decrease from online, phone and chat; and (iii) a

$3.2 million decrease from net store closings and other. Total Retail smart bed unit sales decreased 8% compared with

the prior year. Total Retail average revenue per smart bed unit decreased by 3% to $5,802, compared with $5,990 in the

prior-year period.

Gross profit

Gross profit of $241 million for the three months ended June 29, 2024 decreased by $23 million, or 9%, compared with

$264 million for the same period one year ago. The gross profit rate increased to 59.1% of net sales for the three months

ended June 29, 2024, compared with 57.6% for the prior-year comparable period.

The current-year gross profit rate increase of 1.5 ppt. was mainly due to: (i) improvement in commodity prices and

operating efficiencies, increased the rate by 2.2 ppt.; (ii) favorability in sales return and exchange costs, increased the

rate by 0.7 ppt.; partly offset by (iii) product mix of our FlexFit smart adjustable bases, which pressured the rate by 1.3

ppt. In addition, the gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including

changes in warranty expenses, manufacturing and supply chain operations and performance-based incentive

compensation.

Sales and marketing expenses

Sales and marketing expenses for the three months ended June 29, 2024 were $182 million, or 44.7% of net sales,

compared with $198 million, or 43.1% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate increase of 1.6 ppt. was primarily due to the deleveraging impact of an 11% net sales decline

offset by an 8% decrease in expenses including a 7% lower media spend.

General and administrative expenses

General and administrative (G&A) expenses totaled $40 million, or 9.7% of net sales, for the three months ended

June 29, 2024, compared with $40 million, or 8.7% of net sales, in the prior-year period. The $0.2 million decrease in

G&A expenses consisted mainly of: (i) a $1.8 million decrease in employee compensation on lower headcount; offset by

(ii) a $1.0 million year-over-year increase in company-wide, performance-based incentive compensation due to the

expected performance against the full-year targets in the current year; and (iii) $0.6 increase in other miscellaneous

expenses. The G&A expenses rate increased by 1.0 ppt. in the current-year period, compared with the same period one

year ago due to the items discussed above offset by the deleveraging impact of lower net sales.

Research and development expenses

Research and development (R&D) expenses decreased to $12 million for the three months ended June 29, 2024,

compared with $15 million with the same period last year primarily due to lower headcount and outside services. While

the Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained

environment.

Interest expense, net

Interest expense, net increased to $12 million for the three months ended June 29, 2024, compared with $10 million for

the same period one year ago. The $2 million increase was mainly driven by a higher weighted-average interest rate

compared with the same period one year ago.


20 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs

incurred in 2023, the Company incurred an additional $1.8 million and $12.4 million of restructuring costs during the

three and six months ended June 29, 2024, respectively. Charges incurred related to this initiative were comprised of

contract termination costs, severance and employee-related benefits, professional fees and other, and asset impairment

charges and are included in the restructuring costs line in the Company’s consolidated statement of operations. The

Company expects an additional $1 million to $2 million of restructuring costs to be incurred through the remainder of

2024.

Income tax (benefit) expense

Income tax benefit totaled $1.1 million for the three months ended June 29, 2024, compared with income tax expense

of $0.5 million for the same period last year. The change in income tax benefit/expense was primarily due to the impact

of (loss) income before income tax levels.

Comparison of Six Months Ended June 29, 2024 with Six Months Ended July 1, 2023

Net sales

Net sales for the six months ended June 29, 2024 decreased by $106 million, or 11%, to $879 million, compared with

$985 million for the same period one year ago. The mattress industry is in a historic recession, consumer purchasing

power remains limited, and consumers are scrutinizing their spending.

The net sales decrease consisted primarily of an 11% comparable sales decrease in Total Retail. For additional details,

see the components of total net sales change on page 19.

The $106 million net sales decrease compared with the same period one year ago was comprised of the following: (i) an

$84 million decrease in Retail comparable net sales; (ii) a $19 million decrease in online, phone and other sales; and (iii) a

$3 million decrease resulting from net store closings. Total smart bed unit sales declined 9% compared with the same

period one year ago. Average revenue per smart bed unit in Total Retail decreased by 2% to $5,782, compared with

$5,913 in the prior-year period.

Gross profit

Gross profit of $518 million for the six months ended June 29, 2024 decreased by $57 million, or 10%, compared with

$575 million for the same period one year ago. The gross profit rate increased to 58.9% of net sales for the six months

ended June 29, 2024, compared to 58.3% in the prior-year comparable period.

The current-year gross profit rate increase of 0.6 ppt. was impacted by: (i) improvement in commodity prices and

operating efficiencies, increased the rate by 1.6 ppt.; (ii) favorability in sales return and exchange costs, increased the

rate by 0.3 ppt.; partly offset by (iii) product mix of our FlexFit smart adjustable bases, which pressured the rate by 1.3

ppt. In addition, the gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including

changes in warranty expenses, manufacturing and supply chain operations and performance-based incentive

compensation.

Sales and marketing expenses

Sales and marketing expenses for the six months ended June 29, 2024 were $391 million, or 44.5% of net sales,

compared with $428 million, or 43.5% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate increase of 1.0 ppt. was primarily due to deleveraging impact of a 11% net sales decline offset

by a 9% decrease in expenses including 8% lower media spend.


21 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

General and administrative expenses

General and administrative (G&A) expenses totaled $79 million, or 8.9% of net sales, for the six months ended June 29,

2024, compared with $79 million, or 8.0% of net sales, in the prior-year period. The $0.5 million decrease in G&A

expenses consisted of: (i) a $3.0 million reduction in employee compensation on lower headcount; (ii) a $1.2 million

decrease in other occupancy expenses; largely offset by (iii) an increase in miscellaneous other expenses, which

benefited during the same period one year ago from legal and insurance settlements of $1.8 million; and (iv) a $1.1

million increase in depreciation and amortization. The G&A expenses rate increased by 0.9 ppt. in the current-year

period, compared with the same period one year ago due to the deleveraging impact of the 11% net sales decrease

partially offset by the net expense reductions discussed above.

Research and development expenses

Research and development (R&D) expenses decreased by 20% to $24 million for the six months ended June 29, 2024,

compared with $30 million for the same period one year ago on lower outside services and headcount. While the

Company’s consumer innovation pipeline remains robust, it is reprioritizing R&D resources in this highly constrained

environment.

Interest expense, net

Interest expense, net increased to $25 million for the six months ended June 29, 2024, compared with $19 million for the

same period one year ago. The $6 million increase was mainly driven by a higher weighted-average interest rate

compared with the same period one year ago.

Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs

incurred in 2023, the Company incurred $12.4 million of restructuring costs in the first six months of 2024. Charges

incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,

professional fees and other, and asset impairment charges and are included in the restructuring costs line in the

Company’s consolidated statement of operations. The Company expects an additional $1 million to $2 million of

restructuring costs to be incurred through the remainder of 2024.

Income tax (benefit) expense

Income tax benefit totaled $0.4 million for the six months ended June 29, 2024, compared with income tax expense of

$6 million last year. The change in income tax expense was primarily due to the change in (loss) income before income

taxes levels and the impact of discrete tax expenses. Discrete tax expense, primarily stock-based compensation tax

shortfalls, was $2.4 million for the six months ended June 29, 2024, compared to $1.0 million for the same period last

year.

Liquidity and Capital Resources

Managing liquidity and capital resources is an important part of the Company’s commitment to deliver superior

shareholder value over time. The Company’s primary sources of liquidity are cash flows provided by operating activities

and cash available under its $680 million revolving credit facility, as amended. As of June 29, 2024, the Company does

not have any off-balance sheet financing other than its $7 million in outstanding letters of credit. The cash generated

from ongoing operations and cash available under the revolving credit facility are expected to be adequate to maintain

operations, and fund anticipated expansion, strategic initiatives and contractual obligations such as lease payments and

capital commitments for new retail stores for the foreseeable future.

Changes in cash and cash equivalents during the six months ended June 29, 2024 primarily consisted of $24 million of

cash provided by operating activities, a $6 million decrease in short-term borrowings which included a decrease of $7

million in book overdrafts, partly offset by an increase of $1 million in the revolving credit facility, $14 million of cash

used to purchase property and equipment and $3 million of cash used to issue notes receivable.


22 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

The following table summarizes cash flows (in millions). Amounts may not add due to rounding differences:


	Six Months Ended
	June 29, 2024	July 1, 2023
Total cash provided by (used in):
Operating activities	$23.5	$18.7
Investing activities	(17.0)	(30.3)
Financing activities	(7.0)	11.6
Net (decrease) increase in cash and cash equivalents	$(0.5)	$0.0

Cash provided by operating activities for the six months ended June 29, 2024 was $24 million, compared with $19

million for the six months ended July 1, 2023. Significant components of the year-over-year change in cash provided by

operating activities included: (i) a $27 million fluctuation in inventory due to lower sales volumes and operational

improvements; (ii) a $10 million fluctuation in customer prepayments; partially offset by (iii) a $25 million decrease in net

income for the six months ended June 29, 2024 compared with the six months ended July 1, 2023; and (iv) an $8 million

fluctuation in accounts payable due to timing of vendor payments.

Net cash used in investing activities to purchase property and equipment was $14 million for the six months ended

June 29, 2024, compared with $30 million for the same period one year ago. In addition, the Company issued $3 million

of notes receivable during the six months ended June 29, 2024.

Net cash used in financing activities was $7 million for the six months ended June 29, 2024, compared with net cash

provided by financing activities of $12 million for the same period last year. Short-term borrowings decreased by $6

million during the current-year period due to a $1 million increase in borrowings under the revolving credit facility to

$540 million and a $7 million decrease in book overdrafts, which are included in the net change in short-term

borrowings. During the six months ended June 29, 2024, the Company repurchased $1 million of its stock compared

with $4 million (based on settlement dates, in connection with the vesting of employee restricted stock awards) during

the same period one year ago. The Company made no share repurchases under its Board-approved share repurchase

program in either period.

In the second quarter of fiscal 2022, the Company suspended share repurchases under its Board-approved share

repurchase program. At June 29, 2024, there was $348 million remaining authorization under the Board-approved

$600 million share repurchase program. There is no expiration date governing the period over which the Company can

repurchase shares.

At June 29, 2024, the Company had $540 million of borrowings under its revolving credit facility, $7 million in

outstanding letters of credit and net liquidity available under the credit facility of $133 million. Total availability under its

revolving credit facility was $680 million, which amortizes by $2.5 million per quarter through December 2026. At

June 29, 2024, the Company’s leverage ratio as defined in the credit agreement was 4.4x versus the permissible net

leverage ratio of 5.5x, the weighted-average interest rate on borrowings under the credit facility was 8.4% and the

Company was in compliance with all financial covenants.


23 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Non-GAAP Data Reconciliations

Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)

The Company defines earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net income

plus: income tax expense, interest expense, depreciation and amortization, stock-based compensation, restructuring

costs and asset impairments. Management believes Adjusted EBITDA is a useful indicator of its financial performance

and its ability to generate cash from operating activities. The Company’s definition of Adjusted EBITDA may not be

comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which

is a non-GAAP financial measure, to the comparable GAAP financial measure.

Adjusted EBITDA calculations are as follows (in thousands):


	Three Months Ended		Trailing-Twelve Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Net (loss) income	$(5,051)	$754	$(40,039)	$11,822
Income tax (benefit) expense	(1,099)	524	(10,730)	6,602
Interest expense	12,270	9,948	48,214	32,289
Depreciation and amortization	16,347	18,304	69,676	71,318
Stock-based compensation	3,992	5,252	13,073	15,071
Restructuring costs	1,819	—	28,147	—
Asset impairments	—	170	490	294
Adjusted EBITDA	$28,278	$34,952	$108,831	$137,396

Free Cash Flow

The Company’s “free cash flow” data is considered a non-GAAP financial measure and is not in accordance with, or

preferable to, “net cash provided by operating activities,” or GAAP financial data. However, the Company is providing

this information as it believes it facilitates analysis for investors and financial analysts.

The following table summarizes free cash flow calculations (in thousands):


	Six Months Ended		Trailing-Twelve Months Ended
	June 29, 2024	July 1, 2023	June 29, 2024	July 1, 2023
Net cash provided by (used in) operating activities	$23,518	$18,720	$(4,230)	$26,167
Subtract: Purchases of property and equipment	14,075	29,899	41,232	62,794
Free cash flow	$9,443	$(11,179)	$(45,462)	$(36,627)

Index


24 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Non-GAAP Data Reconciliations (continued)

Return on Invested Capital (Adjusted ROIC)

Adjusted ROIC is a financial measure the Company uses to determine how efficiently it deploys its capital. It quantifies

the return the Company earns on its adjusted invested capital. Management believes Adjusted ROIC is also a useful

metric for investors and financial analysts. The Company computes Adjusted ROIC as outlined below. Its definition and

calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other

companies.

The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested

capital, which are non-GAAP financial measures, to the comparable GAAP financial measures (in thousands):


	Trailing-Twelve Months Ended
	June 29, 2024	July 1, 2023
Adjusted net operating profit after taxes (Adjusted NOPAT)
Operating (loss) income	$(2,555)	$50,713
Add: Operating lease expense (1)	27,750	27,040
Less: Income taxes (2)	(6,104)	(21,993)
Adjusted NOPAT	$19,091	$55,760

Average adjusted invested capital
Total deficit	$(446,964)	$(419,141)
Add: Long-term debt (3)	540,480	484,161
Add: Operating lease obligations (4)	408,724	438,483
Total adjusted invested capital at end of period	$502,240	$503,503

Average adjusted invested capital (5)	$509,369	$452,573

Adjusted return on invested capital (Adjusted ROIC) (6)	3.7%	12.3%

___________________________

(1) Represents the interest expense component of lease expense included in the Company’s financial statements under ASC 842, Leases.

(2) Reflects annual effective income tax rates, before discrete adjustments, of 24.2% and 28.3% for June 29, 2024 and July 1, 2023, respectively.

(3) Long-term debt includes existing finance lease liabilities.

(4) Reflects operating lease liabilities included in the Company’s financial statements under ASC 842.

(5) Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.

(6) Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.

Note - the Company’s adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable

to, GAAP financial data. However, the Company is providing this information as it believe it facilitates analysis of the Company's financial performance

by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

Critical Accounting Policies

The Company discusses its critical accounting policies and estimates in Management’s Discussion and Analysis of

Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the fiscal year ended

December 30, 2023. There were no significant changes in the Company’s critical accounting policies since the end of

fiscal 2023.

Index


25 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to changes in market-based short-term interest rates that will impact net interest expense. If

overall interest rates were one percentage point higher than current rates, annual net income would decrease by

$4.1 million based on the $540 million of borrowings under the credit facility at June 29, 2024. The Company does not

manage the interest-rate volatility risk of borrowings under the credit facility through the use of derivative instruments.

ITEM 4. CONTROLS AND PROCEDURES

Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), that are

designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under

the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time

periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is

accumulated and communicated to the Company’s management, including its principal executive officer and principal

financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required

disclosure. The Company’s management, with the participation of its principal executive officer and principal financial

officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as

of the end of the period covered by this quarterly report. Based on this evaluation, its principal executive officer and

principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of the end

of the period covered by this quarterly report.

Changes in Internal Control

There were no changes in the Company’s internal control over financial reporting during the fiscal quarter ended

June 29, 2024, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control

over financial reporting.

Index


26 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company’s legal proceedings are discussed in Note 13, Commitments and Contingencies, Legal Proceedings, in the

Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

ITEM 1A. RISK FACTORS

The Company’s business, financial condition and operating results are subject to a number of risks and uncertainties,

including both those that are specific to the Company’s business and others that affect all businesses operating in a

global environment. Investors should carefully consider the information in this report under the heading, Management’s

Discussion and Analysis of Financial Condition and Results of Operations, and also the information under the heading,

Risk Factors, in the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form

10-Q. The risk factors discussed in the Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q

including this Quarterly Report on Form 10-Q do not identify all risks that the Company faces because its business

operations could also be affected by additional risk factors that are not presently known to the Company or that it

currently considers to be immaterial to its operations.

Index


27 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS, AND ISSUER PURCHASES OF

EQUITY SECURITIES

(a) – (b) Not applicable.


Period	Total Number of Shares Purchased(1)(2)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3)
March 31, 2024 through April 27, 2024	1,320	$13.28	—	$348,071,000
April 28, 2024 through May 25, 2024	1,096	$15.96	—	$348,071,000
May 26, 2024 through June 29, 2024	588	$12.60	—	$348,071,000
Total	3,004	$14.13	—	$348,071,000

___________________________

(1)The Company did not purchase any shares under its Board-approved $600 million share repurchase program (effective April 4, 2021), during the

three months ended June 29, 2024.

(2)In connection with the vesting of employee restricted stock grants, the Company repurchased 3,004 shares of its common stock at a cost of

$42 thousand during the three months ended June 29, 2024.

(3)There is no expiration date governing the period over which the Company can repurchase shares under its Board-approved share repurchase

program. Any repurchased shares are constructively retired and returned to an unissued status.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plan and Non-rule 10b5-1 Trading Arrangement Adoptions, Modifications and Terminations

None of the Company’s directors or officers adopted, modified or terminated any contract, instruction or written plan for

the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule

10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of SEC Regulation S-K, during the

quarter ended June 29, 2024.

Index


28 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

ITEM 6. EXHIBITS


Exhibit Number		Description
10.1†		Amendment No. 1 to the Sleep Number Corporation 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 contained in Sleep Number’s Current Report on Form 8-K filed May 21, 2024 (File No. 000-25121))
31.1*		Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2*		Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
101.INS*		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Filed Herein.

† Management contract or compensatory plan or arrangement.

Index


29 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned thereunto duly authorized.


		SLEEP NUMBER CORPORATION
		(Registrant)

Dated:	August 6, 2024	By:	/s/ Shelly R. Ibach
			Shelly R. Ibach
			Chief Executive Officer
			(principal executive officer)

		By:	/s/ Joel J. Laing
			Joel J. Laing
			Chief Accounting Officer
			(principal accounting officer)

Index


30 \| 2Q 2024 FORM 10-Q		SLEEP NUMBER CORPORATION

Exhibit 31.1

Certification by Chief Executive Officer

I, Shelly R. Ibach, certify that:

1.I have reviewed this Quarterly report on Form 10-Q of Sleep Number Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 6, 2024

			/s/ Shelly R. Ibach
			Shelly R. Ibach
			Chief Executive Officer

Exhibit 31.2

Certification by Chief Financial Officer

I, Francis K. Lee, certify that:

1.I have reviewed this Quarterly report on Form 10-Q of Sleep Number Corporation;

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 6, 2024
			/s/ Francis K. Lee
			Francis K. Lee
			Executive Vice President and Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sleep Number Corporation (the “Company”) on Form 10-Q for the period ended June 29, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Shelly R. Ibach, Chief Executive Officer of the Company, solely for the purposes of 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, does hereby certify, to her knowledge, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 6, 2024

			/s/ Shelly R. Ibach
			Shelly R. Ibach
			Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sleep Number Corporation (the “Company”) on Form 10-Q for the period ended June 29, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Francis K. Lee, Executive Vice President and Chief Financial Officer of the Company, solely for the purposes of 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, does hereby certify, to his knowledge, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 6, 2024

			/s/ Francis K. Lee
			Francis K. Lee
			Executive Vice President and Chief Financial Officer

Cover Page	6 Months Ended
Cover Page	Jun. 29, 2024 shares
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 29, 2024
Document Transition Report	false
Entity File Number	000-25121
Entity Registrant Name	SLEEP NUMBER CORPORATION
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1597886
Entity Address, Address Line One	1001 Third Avenue South
Entity Address, City or Town	Minneapolis,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55404
City Area Code	763
Local Phone Number	551-7000
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	SNBR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	22,355,000
Entity Central Index Key	0000827187
Current Fiscal Year End Date	--12-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,020	$ 2,539
Accounts receivable, net of allowances of $1,098 and $1,437, respectively	20,272	26,859
Inventories	95,845	115,433
Prepaid expenses	21,322	16,660
Other current assets	37,925	44,637
Total current assets	177,384	206,128
Non-current assets:
Property and equipment, net	153,676	179,503
Operating lease right-of-use assets	373,518	395,411
Goodwill and intangible assets, net	66,523	66,634
Deferred income taxes	25,397	20,253
Other non-current assets	87,147	82,951
Total assets	883,645	950,880
Current liabilities:
Borrowings under revolving credit facility	540,200	539,500
Accounts payable	106,039	135,901
Customer prepayments	44,518	49,143
Accrued sales returns	20,531	22,402
Compensation and benefits	35,305	28,273
Taxes and withholding	16,563	17,134
Operating lease liabilities	80,914	81,760
Other current liabilities	56,500	61,958
Total current liabilities	900,570	936,071
Non-current liabilities:
Operating lease liabilities	327,810	351,394
Other non-current liabilities	102,229	105,343
Total liabilities	1,330,609	1,392,808
Shareholders’ deficit:
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.01 par value; 142,500 shares authorized, 22,355 and 22,235 shares issued and outstanding, respectively	224	222
Additional paid-in capital	24,211	16,716
Accumulated deficit	(471,399)	(458,866)
Total shareholders’ deficit	(446,964)	(441,928)
Total liabilities and shareholders’ deficit	$ 883,645	$ 950,880

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Current assets:
Allowances	$ 1,098	$ 1,437
Shareholders’ deficit:
Undesignated preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Undesignated preferred stock, shares issued (in shares)	0	0
Undesignated preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	142,500,000	142,500,000
Common stock, shares issued (in shares)	22,355,000	22,235,000
Common stock, shares outstanding (in shares)	22,355,000	22,235,000

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Income Statement [Abstract]
Net sales	$ 408,413	$ 458,789	$ 878,862	$ 985,316
Cost of sales	166,923	194,544	361,198	410,806
Gross profit	241,490	264,245	517,664	574,510
Operating expenses:
Sales and marketing	182,400	197,779	390,912	428,267
General and administrative	39,573	39,795	78,652	79,196
Research and development	11,578	15,445	24,019	29,888
Total operating expenses	235,370	253,019	506,002	537,351
Operating income	6,120	11,226	11,662	37,159
Interest expense, net	12,270	9,948	24,569	19,050
(Loss) income before income taxes	(6,150)	1,278	(12,907)	18,109
Income tax (benefit) expense	(1,099)	524	(374)	5,890
Net (loss) income	$ (5,051)	$ 754	$ (12,533)	$ 12,219
Basic net (loss) income per share:
Net (loss) income per share – basic (in dollars per share)	$ (0.22)	$ 0.03	$ (0.56)	$ 0.55
Weighted-average shares – basic (in shares)	22,614	22,460	22,560	22,378
Diluted net (loss) income per share:
Net (loss) income per share – diluted (in dollars per share)	$ (0.22)	$ 0.03	$ (0.56)	$ 0.54
Weighted-average shares – diluted (in shares)	22,614	22,502	22,560	22,543
Restructuring Costs and Asset Impairment Charges	$ 1,819	$ 0	$ 12,419	$ 0

Condensed Consolidated Statements of Shareholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		22,014
Beginning balance at Dec. 31, 2022	$ (438,177)	$ 220	$ 5,182	$ (443,579)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	11,465			11,465
Exercise of common stock options (in shares)		17
Exercise of common stock options	389		389
Stock-based compensation (in shares)		271
Stock-based compensation	4,639	$ 3	4,636
Repurchases of common stock (in shares)		(118)
Repurchases of common stock	(3,363)	$ (1)	(3,362)
Ending balance (in shares) at Apr. 01, 2023		22,184
Ending balance at Apr. 01, 2023	(425,047)	$ 222	6,845	(432,114)
Beginning balance (in shares) at Dec. 31, 2022		22,014
Beginning balance at Dec. 31, 2022	(438,177)	$ 220	5,182	(443,579)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	12,219
Ending balance (in shares) at Jul. 01, 2023		22,214
Ending balance at Jul. 01, 2023	(419,141)	$ 222	11,997	(431,360)
Beginning balance (in shares) at Apr. 01, 2023		22,184
Beginning balance at Apr. 01, 2023	(425,047)	$ 222	6,845	(432,114)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	754			754
Exercise of common stock options (in shares)		3
Exercise of common stock options	39		39
Stock-based compensation (in shares)		33
Stock-based compensation	5,251	$ 0	5,251
Repurchases of common stock (in shares)		(6)
Repurchases of common stock	(138)	$ 0	(138)	0
Ending balance (in shares) at Jul. 01, 2023		22,214
Ending balance at Jul. 01, 2023	$ (419,141)	$ 222	11,997	(431,360)
Beginning balance (in shares) at Dec. 30, 2023	22,235	22,235
Beginning balance at Dec. 30, 2023	$ (441,928)	$ 222	16,716	(458,866)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(7,482)			(7,482)
Stock-based compensation (in shares)		134
Stock-based compensation	4,117	$ 1	4,116
Repurchases of common stock (in shares)		(43)
Repurchases of common stock	(570)		(570)
Ending balance (in shares) at Mar. 30, 2024		22,326
Ending balance at Mar. 30, 2024	$ (445,863)	$ 223	20,262	(466,348)
Beginning balance (in shares) at Dec. 30, 2023	22,235	22,235
Beginning balance at Dec. 30, 2023	$ (441,928)	$ 222	16,716	(458,866)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	$ (12,533)
Ending balance (in shares) at Jun. 29, 2024	22,355	22,355
Ending balance at Jun. 29, 2024	$ (446,964)	$ 224	24,211	(471,399)
Beginning balance (in shares) at Mar. 30, 2024		22,326
Beginning balance at Mar. 30, 2024	(445,863)	$ 223	20,262	(466,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(5,051)			(5,051)
Stock-based compensation (in shares)		32
Stock-based compensation	3,992	$ 1	3,991
Repurchases of common stock (in shares)		(3)
Repurchases of common stock	$ (42)		(42)
Ending balance (in shares) at Jun. 29, 2024	22,355	22,355
Ending balance at Jun. 29, 2024	$ (446,964)	$ 224	$ 24,211	$ (471,399)

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Cash flows from operating activities:
Net (loss) income	$ (12,533)	$ 12,219
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	34,177	36,749
Stock-based compensation	8,109	9,890
Net loss on disposals and impairments of assets	2,500	181
Deferred income taxes	(5,144)	(8,272)
Changes in operating assets and liabilities:
Accounts receivable	6,587	1,903
Inventories	19,588	(7,412)
Income taxes	774	1,808
Prepaid expenses and other assets	(1,483)	(5,824)
Accounts payable	(18,464)	(10,244)
Customer prepayments	(4,625)	(14,683)
Accrued compensation and benefits	7,153	7,594
Other taxes and withholding	(1,345)	(2,074)
Other accruals and liabilities	(11,776)	(3,115)
Net cash provided by operating activities	23,518	18,720
Cash flows from investing activities:
Purchases of property and equipment	(14,075)	(29,899)
Issuance of note receivable	(2,942)	(435)
Net cash used in investing activities	(17,017)	(30,334)
Cash flows from financing activities:
Net (decrease) increase in short-term borrowings	(6,408)	14,693
Repurchases of common stock	(612)	(3,501)
Proceeds from issuance of common stock	0	428
Net cash (used in) provided by financing activities	(7,020)	11,620
Net (decrease) increase in cash and cash equivalents	(519)	6
Cash and cash equivalents, at beginning of period	2,539	1,792
Cash and cash equivalents, at end of period	$ 2,020	$ 1,798

Business and Summary of Significant Accounting Policies	6 Months Ended
Business and Summary of Significant Accounting Policies	Jun. 29, 2024
Accounting Policies [Abstract]
Business and Summary of Significant Accounting Policies	Business and Summary of Significant Accounting Policies Business & Basis of Presentation The Company prepared the condensed consolidated financial statements as of and for the three and six months ended June 29, 2024 of Sleep Number Corporation and its 100%-owned subsidiaries (Sleep Number or the Company), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) and they reflect, in the opinion of management, all normal recurring adjustments, including the elimination of all significant intra-entity balances and transactions, necessary to present fairly its financial position as of June 29, 2024 and December 30, 2023, and the consolidated results of operations and cash flows for the periods presented. The historical and quarterly consolidated results of operations may not be indicative of the results that may be achieved for the full year or any future period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the most recent audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023 and other recent filings with the SEC. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of sales, expenses and income taxes during the reporting period. Predicting future events is inherently an imprecise activity and, as such, requires the use of judgment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in these estimates will be reflected in the consolidated financial statements in future periods and could be material. The Company’s critical accounting policies consist of stock-based compensation, warranty liabilities and revenue recognition.

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 29, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements At both June 29, 2024 and December 30, 2023, the Company had $19 million of debt and equity securities that fund the deferred compensation plan and are classified in other non-current assets. The Company also had corresponding deferred compensation plan liabilities of $19 million at both June 29, 2024 and December 30, 2023, which are included in other non-current liabilities. The majority of the debt and equity securities are Level 1 as they trade with sufficient frequency and volume to enable the Company to obtain pricing information on an ongoing basis. Unrealized gains/ (losses) on the debt and equity securities offset those associated with the corresponding deferred compensation plan liabilities.

Inventories

6 Months Ended

Jun. 29, 2024

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in thousands):


	June 29, 2024	December 30, 2023
Raw materials	$7,899	$9,092
Work in progress	94	92
Finished goods	87,852	106,249
	$95,845	$115,433

Goodwill and Intangible Assets, Net

6 Months Ended

Jun. 29, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

Goodwill and Indefinite-lived Intangible Assets

Goodwill was $64 million at June 29, 2024 and December 30, 2023. Indefinite-lived trade name/trademarks totaled $1.4

million at both June 29, 2024 and December 30, 2023.

Definite-lived Intangible Assets

Patents were $2.0 million at both June 29, 2024 and December 30, 2023. Accumulated amortization was $0.9 million at

June 29, 2024 and $0.8 million at December 30, 2023. Amortization expense for both the three months ended June 29,

2024 and July 1, 2023, was $55 thousand, and for both the six months ended June 29, 2024 and July 1, 2023 was

$0.1 million.

Annual amortization for Patents for subsequent years are as follows (in thousands):


2024 (excluding the six months ended June 29, 2024)		$111
2025		226
2026		222
2027		222
2028		155
2029		99
Thereafter		46
Total future amortization for definite-lived intangible assets		$1,081

Credit Agreement

6 Months Ended

Jun. 29, 2024

Debt Disclosure [Abstract]

Credit Agreement